Elite Pharmaceutical, Inc. (OTCBB:ELTP) announced today the launch of Lodrane D in cooperation with ECR Pharmaceuticals, a wholly owned subsidiary of Hi-Tech Pharmacal (Hi-Tech).
Product will be promoted/distributed in the U.S. by ECR and will be available over-the-counter. ELTP expects to receive revenues for the manufacturing, packaging, and laboratory stability study services for Lodrane D, as well as royalties on sales.
Jerry Treppel , Chairman and CEO at Elite, commented:
“ECR and Elite have continued to work diligently to provide a Lodrane product to U.S. consumers.With this launch, we have accomplished this and look forward, in conjunction with our partner ECR, to rebuilding this important allergy-relief franchise. We also look to continue to build and leverage Elite’s technologies through our product pipeline, partnerships and ventures as we continue to systematically meet the milestones we have set for ourselves.”
Elite Pharmaceuticals, Inc.
165 Ludlow Avenue
Northvale, New Jersey 07647
Elite Pharmaceuticals, Inc. specializes in the development of oral controlled release products, such as delayed, sustained, targeted and pulsatile release tables, pellets, capsules, granules and powders. The Company’s primary focus is in the therapeutic areas of pain management, allergy, cardiovascular and infection.